|

January 1 2025

Issue 1 - January 2026

Enabling access to pharmaceutical myopia control with the launch of the new low-dose Labtician Atropine

Labtician is proud to support the Canadian Association of Optometrists’ (CAO) policy position that endorses evidence-based myopia management as a standard of care for all at-risk patients¹. Labtician is enabling access to pharmaceutical myopia control with the launch of the new low-dose Labtician Atropine

Labtician Atropine provides eye care professionals with ready-to-use, precision-manufactured atropine drops to ensure consistent dosing. Available in four precise concentrations 0.01%, 0.02%, 0.025% and 0.05%, Labtician Atropine allows customization of treatment to patient needs and physician preference.

We provide direct-to-patient shipping anywhere in Canada through our pharmacy partners or your preferred retail pharmacy. For more information, email isrs@labtician.com

Discover More preview

Learn more insights and information

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Local Contact For More Information

Need additional information about eye care solutions? Get in touch with us today. We will connect you with your local Territory Manager.

Need additional information about eye care solutions? Get in touch with us today. We will connect you with your local Territory Manager.

"*" indicates required fields

Email Communications*

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.